Fasudil, a Rho-kinase inhibitor, attenuates glomeruloscleros in Dahl salt-sensitive rats

Journal of Hypertension

Volumn 22, Issue 9, 2004, Pages 1787-1796

  Nishikimi, Toshio ^a   Akimoto, Kazumi ^a   Wang, Xin ^a   Mori, Yosuke ^a   Tadokoro, Kazuyoshi ^a   Ishikawa, Yayoi ^a   Shimokawa, Hiroaki ^b   Ono, Hidehiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Fasudil; Hypertension experimental; Nephrosclerosis; Rho kinase; Transforming growth factors

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 2; CREATININE; FASUDIL; PHOSPHOTRANSFERASE INHIBITOR; RENIN; RHO KINASE; RNA; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CREATININE BLOOD LEVEL; EXPERIMENTAL RAT; GLOMERULOSCLEROSIS; HISTOLOGY; HYPERTENSION; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MORPHOLOGY; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SALT INTAKE; SCORING SYSTEM; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; UREA NITROGEN BLOOD LEVEL;

EID: 4344704302     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200409000-00024     Document Type: Article

References (34)

1. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81:153-208.
2. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001; 22:32-39.
3. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389:990-994.
4. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002; 40:751-761.
5. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61:1684-1695.
6. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 2002; 455:169-174.
7. Ishimitsu T, Uehara Y, Numabe A, Tsukada H, Ogawa Y, Iwai J, et al. Interferon gamma attenuates hypertensive renal injury in salt-sensitive Dahl rats. Hypertension 1992; 19:804-808.
8. Nishikimi T, Mori Y, Kobayashi N, Tadokoro K, Wang X, Akimoto K, et al. Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension 2002; 39:1077-1082.
9. 2+ sensitization of prostaglandin F(2alpha)-induced contraction of rabbit aortae. J Physiol 2003; 546: 823-836.
10. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351:95-105.
11. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 1999; 43:1029-1039.
12. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASES J 2001; 15:1062-1064.
13. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93:767-775.
14. Wang X, Nishikimi T, Tadokoro K, Mori Y, Akimoto K, Matsuoka H. Altered gene expression of adrenomedullin and its receptor system and molecular forms of tissue adrenomedullin in left ventricular hypertrophy induced by malignant hypertension. J Hypertens 2003; 21:1171-1181.
15. Yoshihara F, Nishikimi T, Okano I, Horio T, Yutani C, Matsuo H, et al. Alterations of intrarenal adrenomedullin and its receptor system in heart failure rats. Hypertension 2001; 37:216-222.
16. Mori Y, Nishikimi T, Kobayashi N, Ono H, Kangawa K, Matsuoka H. Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. Hypertension 2002; 40:107-113.
17. Nishikimi T, Tadokoro K, Mori Y, Wang X, Akimoto K, Yoshihara F, et al. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats. Hypertension 2003; 41:512-518.
18. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000; 279: H3031-H3039.
19. Nishikimi T, Tadokoro K, Wang X, Mori Y, Asakawa H, Akimoto K, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. Eur J Pharmacol 2002; 453:175-181.
20. Jahner D, Hunter T. The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol Cell Biol 1991; 11:3682-3690.
21. Fritz G, Kaina B. Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death. Biochem Biophys Res Commun 2000; 268: 784-789.
22. Adnane J, Seijo E, Chen Z, Bizouarn F, Leal M, Sebti SM, Munoz-Antonia T. RhoB, not RhoA, represses the transcription of the transforming growth factor beta type II receptor by a mechanism involving activator protein 1. J Biol Chem 2002; 277:8500-8507.
23. Border WA, Noble NA. Cytokines in kidney disease: the role of transforming growth factor-β. Am J Kidney Dis 1993; 22:105-113.
24. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor-β1. Nature 1990; 346:371-374.
25. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993; 92:2597-2601.
26. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 1994; 45:916-927.
27. Horwitz AR, Parsons JT. Cell migration-movin' on. Science 1999; 286:1102-1103.
28. Ishimitsu T, Uehara Y, Numabe A, Tsukada H, Ogawa Y, Yagi S. Antihypertensive effect of interleukin-2 in salt-sensitive Dahl rats. Hypertension 1994; 23:68-73.
29. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 2001; 37:S25-S29.
30. Otsuka F, Yamauchi T, Kataoka H, Mimura Y, Ogura T, Makino H. Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in dahl salt-sensitive rats. Am J Physiol 1998; 274:R1797-R1806.
31. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94:2158-2161.
32. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002; 40:751-761.
33. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38:1307-1310.
34. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105:1545-1547.